Lundbeck Unveils Promising Phase Ib Results for Lu AF28996 in Advanced Parkinson's Disease

Lundbeck Presents Promising Phase Ib Trial Results for Lu AF28996 in Advanced Parkinson's Disease

H. Lundbeck A/S recently showcased findings from their Phase Ib clinical trial on Lu AF28996, a novel oral medication aimed at individuals suffering from advanced Parkinson's disease. This trial's results are being highlighted at the 2026 International Congress of Parkinson's Disease and Movement Disorders (MDS 2026) held in Seoul, South Korea.

Parkinson's disease, a progressive condition marked by the decline of dopamine-producing neurons, poses significant challenges in symptom management. While levodopa remains the mainstay of treatment, many patients experience motor complications that make this management difficult. These complications often include 'ON-and-OFF' fluctuations in symptom control and involuntary movements known as dyskinesia, complicating daily life for those affected.

The Phase Ib trial was designed to evaluate the safety and effectiveness of the investigational Lu AF28996. The trial involved an 18-week open-label format and provided crucial data on the drug's safety and tolerability, demonstrating that most treatment-emergent adverse events were mild in nature. Patients reported common side effects such as nausea, dizziness, and falls, consistent with the mechanisms of action for dopamine agonists.

Study Results: Efficacy on Motor Symptoms

In the trial, participants started with a daily average of 9.5 hours of good symptom control (termed 'Good ON-time'). After 6 weeks of treatment, this increased by 3.6 hours, while periods of OFF-time considerably decreased from an average of 4.7 hours to 2.4 hours. Additionally, troublesome dyskinesia was reduced significantly, lessening the burden of involuntary movements on participants' daily lives.

These promising initial results indicated considerable improvements alongside a need for a reduced levodopa dosage, a testament to Lu AF28996's potential efficacy in managing advanced Parkinson’s disease. Specifically, reductions in mean daily levodopa doses were noted at 53.4% after 6 weeks and 29.2% after 18 weeks of treatment.

Advancing to Phase II: The DARE2 Trial

Encouraged by these outcomes, Lundbeck has moved forward with the Phase II DARE2 trial. This study will evaluate Lu AF28996 in approximately 150 participants who continue to struggle with motor fluctuations despite receiving optimized non-invasive treatments. The primary goal is to assess the drug's ability to increase Good ON-time effectively.

Participants for the DARE2 trial are being recruited across multiple countries, including the United States, the United Kingdom, Italy, Germany, France, and Japan, marking a significant step in establishing Lu AF28996’s efficacy on a larger scale.

Conclusion

The advancing research into Lu AF28996 signifies hope for patients battling advanced stages of Parkinson's disease. With no existing treatments proven to modify the disease's progression, this investigational drug could potentially transform how motor symptoms are managed. Lundbeck's commitment to pushing forward in their research augurs well for the future, reflecting a resilient pursuit of effective therapies in the face of challenging neurological disorders.

As we await further outcomes from the DARE2 trial, the result of this initiative could lay the groundwork for broader applications in treating Parkinson’s disease and improve the quality of life for millions affected by this challenging condition.